Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
1st-line treatment of HER2/neu overexpressing breast cancer
Carcinoma Breast Stage IV
DRUG: Navelbine|DRUG: Herceptin|DRUG: Navelbine (oraly)
Response rate
Time to tumor progression|Overall survival|Safety
The combination of vinorelbine and trastuzumab was demonstrated to be highly effective in several trials showing response rates in the range of 59-78%. This combination is characterized by good tolerability and can be applied for a prolonged period without the risk of major cumulative toxicity The availability of oral vinorelbine promises a further simplification of therapy. The present trial therefore investigates the safety and efficacy of a combined treatment with trastuzumab and oral vinorelbine.